By Marco Patrone A public policy think tank criticizes Ontario’s record of drug approvals, arguing that ‘we should be increasing the drug budget rather than decreasing it.’ The growing backlog in the number of pharmaceuticals approved for funding in Ontario is a result of “cold-hearted” government cost control, a think tank has charged. The Cameron
Health Policy Assembly V October 28-30, 2015 – Banff Conference Centre, Banff AB Personalized Medicine – Will Canadians Benefit or be Denied Access? For complete program and background information please see 2015 Canadian Health Policy Assembly
Coverage for medications in Canada is a patchwork. Sometimes eligibility for coverage is based on postal code, age, and income. These inconsistencies are tough on vulnerable patients. Each stakeholder has a perspective on how to fix this, and it’s long past time for pharmacare programs to be reconstructed with the patient – the end user
Canadian healthcare is not universal. Nowhere is this lack of universality more evident than in the payment for drugs in Canada. Canadians without the financial wherewithal cannot access orphan drugs for rare diseases and take-at-home oral cancer drugs and many other pharmaceuticals. In addition to the physical and emotional tolls experienced, patients and survivors and their
Long-term care residents and care providers in Ontario, Canada participated in a pilot qualitative study of 16 patients living with fecal incontinence and 9 of their healthcare providers in 2 long term care facilities. Subjects were selected equally from both genders. Focus group discussion with study participants used both thematic and deductive approaches; sessions were
This paper is intended to be a briefing document from The Canadian Continence Foundation (TCCF) to help policy-makers formulate evidence-informed policies to meet the unmet needs of Canadians living with incontinence. Incontinence is a chronic condition that carries an enormous stigma. Patients are often reluctant to discuss this issue with their family, friends and physician
Incontinence is a prevalent health condition that is rarely discussed as people living with the condition are often embarrassed to discuss it with their healthcare providers; for many it is a medical taboo, not to be spoken aloud. The continence care community generally agrees that the prevalence of incontinence in Canada is about the same
D Wayne Taylor The Cameron Institute, Cambridge, ON, Canada At the margins of the orphan drug world are found what have become known as dormant drugs or dormant therapies – drugs that have been abandoned as they failed to meet designated clinical endpoints in their development and for whom patents have expired. There are also
D. Wayne Taylor, Michael Weir, Jacqueline J. Cahill, Diaa E. E. Rizk The study aimed to determine the prevalence and understanding of urinary incontinence (UI) in a community sample of Canadian women and identify barriers to health-care seeking. Women aged 20 or more were selected randomly fromthe community and interviewed about inappropriate urine loss within
The Cameron Institute